MEDVi Review

• Names three partner compounding pharmacies: Triad Rx, Red Rock Home Pharmacy and Beaker Pharmacy
• Names the prescriber network — OpenLoop Health, with treatment provided by CareGLP Affiliated P.C.s
• Compounded GLP-1 injections from $179/month; tablets from $249/month (checked 16 September 2026)
• Publishes a full cancellation and refund policy, including a 72-hour cooling-off window
• Free dietician visits and care coaching included, subject to eligibility
• HSA/FSA approved; no insurance required

Compounded GLP-1 injections and tablets, plus branded GLP-1 routes sold as a membership plus medication cost. Prescriptions are issued only after an online consultation with an independent licensed provider. MEDVi states that compounded medications are dispensed by state-licensed pharmacies but are not FDA approved, and that although the facilities are FDA-regulated the medicines are not FDA-approved or evaluated for safety, efficacy or quality.

Online assessment, then a consultation with an OpenLoop Health clinician after checkout, who determines eligibility and retains the prescribing decision. MEDVi states the assessment itself does not create a doctor-patient relationship.

Free, expedited shipping is included on the compounded plans.

MEDVi publishes two compounded routes and three branded ones. Compounded GLP-1 injections start at $179 a month and compounded GLP-1 tablets at $249 a month; the branded options are sold as a $99 membership plus the cost of the medication itself (checked 16 September 2026). That last structure matters when comparing: the $99 is not the price of treatment, it is the price of access, and the medication is charged on top at whatever it costs.

On the compounded plans MEDVi states there is no membership fee and no hidden fee, that no insurance is required, that shipping is free and expedited, and that the plans are HSA/FSA approved. Included in the price it lists the prescription, one-to-one physician guidance, 24/7 support, and free dietician visits and care coaching — though that last item carries an asterisk, qualified as "free to end users subject to insurance and copays eligibility to be determined at time of visit". Read it as conditional rather than bundled.

One ambiguity is worth resolving at intake. The $179 figure appears on the general site as a standing "starting at" price and on the GLP-1 landing page inside a seasonal sale banner. Those are different claims about the same number, and MEDVi does not reconcile them. Ask which price you are on and what it becomes at renewal.

Most telehealth platforms in this segment say "a state-licensed compounding pharmacy" and stop. MEDVi names three: Triad Rx, Red Rock Home Pharmacy, and Beaker Pharmacy's compounding arm, each linked from its own site. It does not say which one fills a given order, but a named pharmacy can be looked up with a state board of pharmacy, and an unnamed one cannot. That is a real difference in what a buyer is able to check.

Prescribing is equally explicit. MEDVi states that OpenLoop Health, a network of US-licensed doctors, applies exclusionary criteria to the intake assessment, that an OpenLoop clinician meets the patient after checkout to determine eligibility, and that "OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s". Medical treatment is provided by CareGLP Affiliated P.C.s together with OpenLoop Health. MEDVi is candid that its own assessment "does not create a doctor-patient relationship" — the relationship is with the clinician network, not with the brand.

On regulatory status MEDVi's wording is among the clearer ones in the segment: compounded medications "are dispensed by state-licensed pharmacies but are not FDA approved", and more fully, that compounded GLP-1s "are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality." The distinction between a regulated facility and a reviewed medicine is one most marketing blurs, and MEDVi draws it.

MEDVi publishes a cancellation and refund policy, which is more than most of its competitors do, and the detail repays reading because it is tighter than the marketing suggests. You may cancel at any time, but the request must reach patient support at least 72 hours before the next billing date; inside that window the next cycle is charged and cancellation takes effect the cycle after. Service continues to the end of the paid cycle.

Refunds are narrower than cancellation. If you cancel within the first 72 hours of the subscription term and have received no services, you get a full refund. If a clinician disqualifies you on medical grounds, you get a full refund — MEDVi states this twice, including for the consultation. Otherwise, on a monthly plan, MEDVi's policy states in capitals that no refund is issued for the month in which cancellation occurs or for any prior month. On plans billed two or more months at a time, months for which no medication shipped are refunded.

The underlying constraint is not MEDVi's invention. As its policy notes, federal rules generally prohibit returning prescription medication to a pharmacy for refund or reuse once it has been dispensed for a patient, which is why no provider in this segment can offer an open-ended refund on shipped medicine. Damaged or incorrect items are handled separately and replaced by the pharmacy on evidence.

MEDVi and Trim Rx open at the same number — $179 a month for compounded GLP-1 — which makes the non-price differences the whole comparison. MEDVi names its pharmacies, names its prescriber network and publishes refund terms; TrimRx names no pharmacy and publishes no refund terms. TrimRx, in exchange, states that its price does not move as the dose changes, which MEDVi does not say either way. One is more transparent about the chain; the other is more explicit about what happens to the bill.

Against Trimi, the difference is how commitment is priced. Trimi's $99 and $125 monthly equivalents require a twelve-month plan paid upfront ($1,188 or $1,500); its month-to-month rates are $175 and $235. MEDVi's $179 asks for no year in advance. Trimi also offers a six-month money-back promise that MEDVi does not match — but Trimi's order becomes final the moment a prescription is issued, where MEDVi's 72-hour window runs from the start of the term.

Against Willow at $299 a month, MEDVi is cheaper at entry, though Willow publishes four named treatment routes against MEDVi's two compounded ones. Across all four, what cannot be compared is effectiveness: each publishes its own outcome figures and each qualifies them in its own small print, MEDVi's noting that its claims are self-reported and that results shown are "not typical".

PCF reviews online programs for comparison purposes only. Provider details, pricing, availability, and medication paths can change. Confirm current terms directly and consult a licensed clinician before making medical decisions.